News

Monitor has published a stream of recommendations designed to create a fairer playing field for service providers competing for National Health Service contracts. 

UK patients with advanced kidney cancer will be disappointed by NICE’s decision to stick with its rejection of Pfizer’s new drug Inlyta for use on the National Health Service.

Pharmaceutical companies that thought of the emerging markets as a solution to their woes in Europe and the USA need to tailor their operations to each individual country.

ReNeuron has become the first corporate partner of the Cell Therapy Catapult, a “centre of transitional excellence for regenerative medicine”, in a pact to develop new cell therapy manufacturing technologies and assays. 

A month after getting approval in the USA, Shionogi says that regulators in Europe are reviewing the firm’s ospemifene to treat women experiencing pain during sexual intercourse.

In final guidance NICE has recommended Forest Lab’s Colobreathe and Novartis’ Tobi Podhaler as options for treating certain lung infections in people with cystic fibrosis.

The PharmaTimes head-to-head debate between Dr Ben Goldacre and Stephen Whitehead is now available on our website at no cost to the viewer.

The PharmaTimes head-to-head debate between Dr Ben Goldacre and Stephen Whitehead is now available on our website.

The NHS will get a new inspectorate and a legal duty of candour will be imposed on hospitals and potentially NHS staff, in tough new measures designed to stop another Mid Staffs from happening again.

Malaysia’s minister of health Liow Tiong Lai has stressed the government’s vision to keep improving the system in the country, having already achieved universal coverage for the population.

The National Institute for Health and Clinical Excellence (NICE) has issued new draft guidance in which it does not recommend Pfizer’s tyrosine kinase inhibitor ((TKI) Xalkori (crizotinib) for use in previously treated anaplastic-lymphoma-kinase-(ALK) positive advanced non-small-cell lung cancer (NSCLC), but has opened a public consultation on this preliminary decision.

Lundbeck could earn up to $825 million after long-time partner Otsuka Pharmaceutical Co expanded the firms’ central nervous system pact to license one of the Danish drugmaker’s investigational Alzheimer’s drugs.

For many Australian pharmaceutical companies, 2012 was an “abysmal” year, and their expectation is that 2013 will be even worse, according to a new report.

European regulators have agreed to review Boehringer Ingelheim and Eli Lilly’s empagliflozin as a treatment for type II diabetes.

US regulators have issued a green light for Biogen Idec’s multiple sclerosis (MS) pill Tecfidera, which industry observers expect will become the king of oral therapies for the disease.